Garda Capital Partners’s Moderna MRNA Stock Holding History

Garda Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300,000	Closed	-$8.85M	–	20
2025 Q4	$8.85M	Hold	300,000	–	–	7.29%	4
2025 Q3	$7.75M	Hold	300,000	–	–	31.09%	1
2025 Q2	$8.28M	Sell	300,000 -20,800	-6%	-$548K	0.2%	128
2025 Q1	$9.09M	Buy	320,800 +300,000	+1,442%	+$10.6M	0.23%	130
2024 Q4	$865K	Sell	20,800 -11,000	-35%	-$526K	0.06%	166
2024 Q3	$2.13M	Sell	31,800 -48,800	-61%	-$4.48M	0.06%	301
2024 Q2	$9.57M	Buy	80,600 +23,300	+41%	+$2.95M	0.34%	89
2024 Q1	$6.11M	Buy	57,300 +30,100	+111%	+$3.03M	0.26%	119
2023 Q4	$2.71M	Sell	27,200 -15,100	-36%	-$1.27M	0.23%	99
2023 Q3	$4.37M	Buy	42,300 +3,000	+8%	+$335K	0.2%	89
2023 Q2	$4.77M	Buy	39,300 +14,900	+61%	+$1.99M	0.27%	89
2023 Q1	$3.75M	Buy	24,400 +11,400	+88%	+$1.88M	0.18%	106
2022 Q4	$2.34M	Buy	+13,000	New	+$2.13M	0.13%	206

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Garda Capital Partners's MRNA Position: Q4 2024 in Review

Garda Capital Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 25,699 shares — an estimated $1.23M sold.

Garda Capital Partners first reported a position in MRNA in Q1 2023 and held it in 4 quarters. The position peaked at $2.53M in Q3 2023. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

Garda Capital Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
Garda Capital Partners sold 25,699 Moderna shares in Q4 2024, an estimated $1.23M.
Garda Capital Partners first reported a position in Moderna in Q1 2023 and held it in 4 quarters.
Garda Capital Partners's Moderna position peaked at $2.53M in Q3 2023.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Garda Capital Partners's 13F filing for Q4 2024, filed 5 Feb 2025.